108 related articles for article (PubMed ID: 32515069)
1. The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Nishiyama-Fujita Y; Nakazato T; Kamiya T; Mizuno K; Ito C; Ogura S; Sakurai A; Tanigawa T; Akimoto M; Aisa Y
Hematol Oncol; 2020 Oct; 38(4):611-613. PubMed ID: 32515069
[No Abstract] [Full Text] [Related]
2. Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.
Kenealy M; Hertzberg M; Benson W; Taylor K; Cunningham I; Stevenson W; Hiwase D; Eek R; Zantomio D; Jong S; Wall M; Blombery P; Gerber T; Debrincat M; Zannino D; Seymour JF
Haematologica; 2019 Apr; 104(4):700-709. PubMed ID: 30545923
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
Mozessohn L; Cheung MC; Fallahpour S; Gill T; Maloul A; Zhang L; Lau O; Buckstein R
Br J Haematol; 2018 Jun; 181(6):803-815. PubMed ID: 29767427
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine.
Sakurai A; Nakazato T
Leuk Lymphoma; 2020 Dec; 61(12):2995-2997. PubMed ID: 32654579
[No Abstract] [Full Text] [Related]
6. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Prebet T; Charbonnier A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
Leuk Lymphoma; 2013 Jul; 54(7):1538-40. PubMed ID: 23110702
[No Abstract] [Full Text] [Related]
7. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
[TBL] [Abstract][Full Text] [Related]
8. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
Solly F; Koering C; Mohamed AM; Maucort-Boulch D; Robert G; Auberger P; Flandrin-Gresta P; Adès L; Fenaux P; Kosmider O; Tavernier-Tardy E; Cornillon J; Guyotat D; Campos L; Mortreux F; Wattel E
Clin Cancer Res; 2017 Jun; 23(12):3025-3034. PubMed ID: 27881579
[No Abstract] [Full Text] [Related]
9. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
10. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
11. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
[TBL] [Abstract][Full Text] [Related]
12. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.
Prébet T; Gore SD; Thépot S; Esterni B; Quesnel B; Beyne Rauzy O; Dreyfus F; Gardin C; Fenaux P; Vey N
Br J Haematol; 2012 Jun; 157(6):764-6. PubMed ID: 22390719
[No Abstract] [Full Text] [Related]
13. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Sébert M; Renneville A; Bally C; Peterlin P; Beyne-Rauzy O; Legros L; Gourin MP; Sanhes L; Wattel E; Gyan E; Park S; Stamatoullas A; Banos A; Laribi K; Jueliger S; Bevan L; Chermat F; Sapena R; Nibourel O; Chaffaut C; Chevret S; Preudhomme C; Adès L; Fenaux P;
Haematologica; 2019 Aug; 104(8):1565-1571. PubMed ID: 30733271
[TBL] [Abstract][Full Text] [Related]
15. Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Scherman E; Malak S; Perot C; Gorin NC; Rubio MT; Isnard F
Leukemia; 2012 Apr; 26(4):822-4. PubMed ID: 21997572
[No Abstract] [Full Text] [Related]
16. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Abaza YM; Kadia TM; Jabbour EJ; Konopleva MY; Borthakur G; Ferrajoli A; Estrov Z; Wierda WG; Alfonso A; Chong TH; Chuah C; Koh LP; Goh BC; Chang JE; Durkes DE; Foudray MC; Kantarjian HM; Dong XQ; Garcia-Manero G
Cancer; 2017 Dec; 123(24):4851-4859. PubMed ID: 28841236
[TBL] [Abstract][Full Text] [Related]
17. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Wanquet A; Prebet T; Berthon C; Sebert M; Roux C; Kulasekararaj A; Micol JB; Esterni B; Itzykson R; Thepot S; Recher C; Delaunay J; Dreyfus F; Mufti G; Fenaux P; Vey N
Am J Hematol; 2015 Oct; 90(10):859-63. PubMed ID: 26113240
[TBL] [Abstract][Full Text] [Related]
18. Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine.
Martín I; Navarro B; Serrano A; Villamón E; Calabuig M; Solano C; Chaves FJ; Yagüe N; Orts M; Amat P; Fuentes A; Seda E; García F; Hernández-Boluda JC; Tormo M
Ann Hematol; 2020 Mar; 99(3):527-537. PubMed ID: 31989250
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
